Literature DB >> 19212314

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

E T Morgan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19212314      PMCID： PMC3139248          DOI： 10.1038/clpt.2008.302

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  33 in total

1.  Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity.

Authors:  Y Tian; S Ke; M S Denison; A B Rabson; M A Gallo
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

2.  Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site.

Authors:  H Iber; Q Chen; P Y Cheng; E T Morgan
Journal:  Arch Biochem Biophys       Date:  2000-05-01       Impact factor: 4.013

3.  Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy.

Authors:  J Elkahwaji; M A Robin; A Berson; M Tinel; P Lettéron; G Labbe; P Beaune; D Elias; P Rougier; B Escudier; P Duvillard; D Pessayre
Journal:  Biochem Pharmacol       Date:  1999-04-15       Impact factor: 5.858

4.  Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes.

Authors:  Jeffrey A Sunman; Roy L Hawke; Edward L LeCluyse; Angela D M Kashuba
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

5.  Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved.

Authors:  Ramiro Jover; Roque Bort; M José Gómez-Lechón; José V Castell
Journal:  FASEB J       Date:  2002-09-19       Impact factor: 5.191

6.  Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver.

Authors:  De-Xiang Xu; Wei Wei; Mei-Fang Sun; Cheng-Yi Wu; Jian-Ping Wang; Ling-Zhen Wei; Cheng-Fan Zhou
Journal:  Free Radic Biol Med       Date:  2004-07-01       Impact factor: 7.376

7.  A novel lipopolysaccharide-modulated Jun binding repressor in intron 2 of CYP2E1.

Authors:  Niclas Tindberg; Inger Bengtsson; Yin Hu
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

Review 8.  Cytochrome P450 regulation and drug biotransformation during inflammation and infection.

Authors:  Kenneth W Renton
Journal:  Curr Drug Metab       Date:  2004-06       Impact factor: 3.731

9.  Altered theophylline clearance during an influenza B outbreak.

Authors:  M J Kraemer; C T Furukawa; J R Koup; G G Shapiro; W E Pierson; C W Bierman
Journal:  Pediatrics       Date:  1982-04       Impact factor: 7.124

10.  TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease.

Authors:  Madhusudana R Chaluvadi; Beatrice A Nyagode; Ryan D Kinloch; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2008-11-06       Impact factor: 5.858
View more
  132 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 2.  Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.

Authors:  Joseph L Tan; Jacques G Eastment; Arjun Poudel; Ruth E Hubbard
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 3.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

4.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

Review 5.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

6.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

7.  Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Authors:  Jane R Kenny; Maggie M Liu; Andrew T Chow; Justin C Earp; Raymond Evers; J Greg Slatter; Diane D Wang; Lei Zhang; Honghui Zhou
Journal:  AAPS J       Date:  2013-06-21       Impact factor: 4.009

8.  Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?

Authors:  Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2009-12-17       Impact factor: 4.030

9.  Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.

Authors:  Hikaru Sato; Takafumi Naito; Takuya Ishida; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2016-08-26       Impact factor: 2.953

10.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.